Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines

Vishwa Jeet Amatya, Yukio Takeshima, Kei Kushitani, Yamada Taketo, Morimoto Chikao, Kouki Inai

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Mesothelioma, a highly aggressive cancer with poor prognosis and refractory to currently available therapies show increasing trends of its incidence in Japan and other developing countries. Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. One of the new treatment strategies for mesothelioma, the humanized anti-CD26 monoclonal antibody therapy is under development. CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies. This study determined the preliminary selection criteria for humanized monoclonal anti-CD26 antibody therapy. Eighty-one epithelioid (49 differentiated and 32 less differentiated), 34 sarcomatoid, 19 biphasic mesothelioma and 8 mesothelioma cell lines were immunohistochemically examined using 8 different commercially available anti-CD26 antibodies for membranous and cytoplasmic expression. The cytoplasmic expression of CD26 was observed in all histological types of mesothelioma, while the membranous expression of CD26 was found in 88% of differentiated and 69% of less differentiated epithelioid mesothelioma, and none of sarcomatoid mesothelioma with anti-CD26 antibodies with rabbit polyclonal anti-DPP4 antibody and similar results were also obtained with goat polyclonal anti-DPP4/CD26 antibody. These antibodies absorbed with soluble human CD26 proteins do not show CD26 expression in mesothelioma tissue, suggesting these two antibodies localize true CD26 protein. Seven mesothelioma cell lines, including sarcomatoid types, also showed membranous expression of CD26 in cellblock preparation. CD26 vector transfection to CD26-negative MSTO-211H cells showed membranous expression of CD26 by flow cytometry, but not in tumor developed in NOD/SCID mice with inoculation of CD26 vector transfected MSTO-211H cells. We found that both rabbit and goat polyclonal antibodies are suitable for immunohistochemical evaluation of membranous expression of CD26 in mesothelioma.

Original languageEnglish
Pages (from-to)1369-1375
Number of pages7
JournalOncology Reports
Volume26
Issue number6
DOIs
Publication statusPublished - 2011 Dec

Fingerprint

Mesothelioma
Cell Line
Anti-Idiotypic Antibodies
Antibodies
Goats
Neoplasms
Monoclonal Antibodies
Rabbits
Dipeptidyl Peptidase 4
Inbred NOD Mouse
SCID Mice
Therapeutics
Patient Selection
Developing Countries
Transfection
Glycoproteins
Flow Cytometry
Japan
Drug Therapy

Keywords

  • CD26
  • Immunohistochemistry
  • Mesothelioma
  • Mesothelioma cell lines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amatya, V. J., Takeshima, Y., Kushitani, K., Taketo, Y., Chikao, M., & Inai, K. (2011). Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncology Reports, 26(6), 1369-1375. https://doi.org/10.3892/or.2011.1449

Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. / Amatya, Vishwa Jeet; Takeshima, Yukio; Kushitani, Kei; Taketo, Yamada; Chikao, Morimoto; Inai, Kouki.

In: Oncology Reports, Vol. 26, No. 6, 12.2011, p. 1369-1375.

Research output: Contribution to journalArticle

Amatya, VJ, Takeshima, Y, Kushitani, K, Taketo, Y, Chikao, M & Inai, K 2011, 'Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines', Oncology Reports, vol. 26, no. 6, pp. 1369-1375. https://doi.org/10.3892/or.2011.1449
Amatya VJ, Takeshima Y, Kushitani K, Taketo Y, Chikao M, Inai K. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncology Reports. 2011 Dec;26(6):1369-1375. https://doi.org/10.3892/or.2011.1449
Amatya, Vishwa Jeet ; Takeshima, Yukio ; Kushitani, Kei ; Taketo, Yamada ; Chikao, Morimoto ; Inai, Kouki. / Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. In: Oncology Reports. 2011 ; Vol. 26, No. 6. pp. 1369-1375.
@article{e7db7fcd06964e0dbe410d38cb3ce6e7,
title = "Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines",
abstract = "Mesothelioma, a highly aggressive cancer with poor prognosis and refractory to currently available therapies show increasing trends of its incidence in Japan and other developing countries. Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. One of the new treatment strategies for mesothelioma, the humanized anti-CD26 monoclonal antibody therapy is under development. CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies. This study determined the preliminary selection criteria for humanized monoclonal anti-CD26 antibody therapy. Eighty-one epithelioid (49 differentiated and 32 less differentiated), 34 sarcomatoid, 19 biphasic mesothelioma and 8 mesothelioma cell lines were immunohistochemically examined using 8 different commercially available anti-CD26 antibodies for membranous and cytoplasmic expression. The cytoplasmic expression of CD26 was observed in all histological types of mesothelioma, while the membranous expression of CD26 was found in 88{\%} of differentiated and 69{\%} of less differentiated epithelioid mesothelioma, and none of sarcomatoid mesothelioma with anti-CD26 antibodies with rabbit polyclonal anti-DPP4 antibody and similar results were also obtained with goat polyclonal anti-DPP4/CD26 antibody. These antibodies absorbed with soluble human CD26 proteins do not show CD26 expression in mesothelioma tissue, suggesting these two antibodies localize true CD26 protein. Seven mesothelioma cell lines, including sarcomatoid types, also showed membranous expression of CD26 in cellblock preparation. CD26 vector transfection to CD26-negative MSTO-211H cells showed membranous expression of CD26 by flow cytometry, but not in tumor developed in NOD/SCID mice with inoculation of CD26 vector transfected MSTO-211H cells. We found that both rabbit and goat polyclonal antibodies are suitable for immunohistochemical evaluation of membranous expression of CD26 in mesothelioma.",
keywords = "CD26, Immunohistochemistry, Mesothelioma, Mesothelioma cell lines",
author = "Amatya, {Vishwa Jeet} and Yukio Takeshima and Kei Kushitani and Yamada Taketo and Morimoto Chikao and Kouki Inai",
year = "2011",
month = "12",
doi = "10.3892/or.2011.1449",
language = "English",
volume = "26",
pages = "1369--1375",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines

AU - Amatya, Vishwa Jeet

AU - Takeshima, Yukio

AU - Kushitani, Kei

AU - Taketo, Yamada

AU - Chikao, Morimoto

AU - Inai, Kouki

PY - 2011/12

Y1 - 2011/12

N2 - Mesothelioma, a highly aggressive cancer with poor prognosis and refractory to currently available therapies show increasing trends of its incidence in Japan and other developing countries. Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. One of the new treatment strategies for mesothelioma, the humanized anti-CD26 monoclonal antibody therapy is under development. CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies. This study determined the preliminary selection criteria for humanized monoclonal anti-CD26 antibody therapy. Eighty-one epithelioid (49 differentiated and 32 less differentiated), 34 sarcomatoid, 19 biphasic mesothelioma and 8 mesothelioma cell lines were immunohistochemically examined using 8 different commercially available anti-CD26 antibodies for membranous and cytoplasmic expression. The cytoplasmic expression of CD26 was observed in all histological types of mesothelioma, while the membranous expression of CD26 was found in 88% of differentiated and 69% of less differentiated epithelioid mesothelioma, and none of sarcomatoid mesothelioma with anti-CD26 antibodies with rabbit polyclonal anti-DPP4 antibody and similar results were also obtained with goat polyclonal anti-DPP4/CD26 antibody. These antibodies absorbed with soluble human CD26 proteins do not show CD26 expression in mesothelioma tissue, suggesting these two antibodies localize true CD26 protein. Seven mesothelioma cell lines, including sarcomatoid types, also showed membranous expression of CD26 in cellblock preparation. CD26 vector transfection to CD26-negative MSTO-211H cells showed membranous expression of CD26 by flow cytometry, but not in tumor developed in NOD/SCID mice with inoculation of CD26 vector transfected MSTO-211H cells. We found that both rabbit and goat polyclonal antibodies are suitable for immunohistochemical evaluation of membranous expression of CD26 in mesothelioma.

AB - Mesothelioma, a highly aggressive cancer with poor prognosis and refractory to currently available therapies show increasing trends of its incidence in Japan and other developing countries. Although surgery is a gold standard for patients with early mesothelioma, most patients with advanced disease are not suitable for surgical resection and have option of palliative chemotherapy alone. One of the new treatment strategies for mesothelioma, the humanized anti-CD26 monoclonal antibody therapy is under development. CD26, a 110-kDa transmembrane glycoprotein with known dipeptidyl peptidase IV activity, plays a role in tumor development and its expression was reported in various human malignancies. This study determined the preliminary selection criteria for humanized monoclonal anti-CD26 antibody therapy. Eighty-one epithelioid (49 differentiated and 32 less differentiated), 34 sarcomatoid, 19 biphasic mesothelioma and 8 mesothelioma cell lines were immunohistochemically examined using 8 different commercially available anti-CD26 antibodies for membranous and cytoplasmic expression. The cytoplasmic expression of CD26 was observed in all histological types of mesothelioma, while the membranous expression of CD26 was found in 88% of differentiated and 69% of less differentiated epithelioid mesothelioma, and none of sarcomatoid mesothelioma with anti-CD26 antibodies with rabbit polyclonal anti-DPP4 antibody and similar results were also obtained with goat polyclonal anti-DPP4/CD26 antibody. These antibodies absorbed with soluble human CD26 proteins do not show CD26 expression in mesothelioma tissue, suggesting these two antibodies localize true CD26 protein. Seven mesothelioma cell lines, including sarcomatoid types, also showed membranous expression of CD26 in cellblock preparation. CD26 vector transfection to CD26-negative MSTO-211H cells showed membranous expression of CD26 by flow cytometry, but not in tumor developed in NOD/SCID mice with inoculation of CD26 vector transfected MSTO-211H cells. We found that both rabbit and goat polyclonal antibodies are suitable for immunohistochemical evaluation of membranous expression of CD26 in mesothelioma.

KW - CD26

KW - Immunohistochemistry

KW - Mesothelioma

KW - Mesothelioma cell lines

UR - http://www.scopus.com/inward/record.url?scp=80053471997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053471997&partnerID=8YFLogxK

U2 - 10.3892/or.2011.1449

DO - 10.3892/or.2011.1449

M3 - Article

VL - 26

SP - 1369

EP - 1375

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -